

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on December 4, 2006

PATENT  
Attorney Docket No.: 021044-005820US  
Client Reference No.: P.0128.02.US

TOWNSEND and TOWNSEND and CREW LLP

By: 

Anna C. Kandel

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

LORENS et al.

Application No.: 10/696,909

Filed: October 29, 2003

For: MODULATORS OF  
ANGIOGENESIS AND  
TUMORIGENESIS

Confirmation No.: 9257

Examiner: Peter J. Redding

Art Unit: 1642

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

Also enclosed is a copy of the supplementary partial European Search report corresponding to the European application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Beth L. Kelly  
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
BLK:ack

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				10/896,909	
				Filing Date	
				October 29, 2003	
First Named Inventor		Lorens, James B.			
Art Unit		1642			
Examiner Name		Peter J. Redding			
Attorney Docket Number		021044-005820US			
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> if known			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> if known				
	B1	WO	2003/76309	A2	12-21-2000	Veasns Interuniversitair Instituut Voor Biotechnologie VZW		<input type="checkbox"/>
	B2	WO	2001/32926	A2	05-10-2001	Curagen Corporation et al.		<input type="checkbox"/>
	B3	WO	2001/63261	A1	09-30-2001	MUSC Foundation for Research Development		<input type="checkbox"/>
	B4	WO	2002/081627	A2	10-17-2002	Allergan, Inc.		<input type="checkbox"/>
	B5	WO	2004/005147	A2	01-22-2004	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	B6	O'DONNELL, K., et al., "Expression of Receptor Tyrosine Kinase Axl and Its Ligand Gas6 in Rheumatoid Arthritis: Evidence for a Novel Endothelial Cell Survival Pathway," <u>American Journal of Pathology</u> , April 1999, Vol. 154, No. 4, pp. 1171-1180.			<input type="checkbox"/>
	B7	ZANTEK, N., et al., "MCF-10A-NeoST: A New Cell System for Studying Cell-ECM and Cell-Cell Interactions in Breast Cancer," <u>Clinical Cancer Research</u> , November 2001, Vol. 7, pp. 3640-3648.			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.